Literature DB >> 2786729

Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.

M Ligo1, Y Nakajima, K Nishikata, A Hoshi.   

Abstract

The in vivo antitumour activities of recombinant human interleukin-2 (rHIL-2) and recombinant human hybrid interferon alpha A/D (rIFN-alpha A/D) were tested in relation to adenocarcinoma 755. The tumour growth, following s.c. inoculation of tumour cells, was inhibited to a greater extent in mice treated with the combination of cytokines than in mice treated with either one alone. Pretreatment with these cytokines did not affect the tumour growth. Injection of tumour-bearing mice with a combination of these cytokines resulted in a marked increase in the total number of lymphocytes in the peritoneal cavity. Among them, Lyt-2+/L3T4- and asialo GM1+ cells were markedly enhanced by the combination of cytokines, and the frequencies of these marker cells were closely correlated with the antitumour activity. In tumour-bearing mice, the size of the thymus was decreased while that of the spleen was increased compared to non-tumour-bearing (normal) mice. Treatment with rHIL-2 caused the thymus, spleen and liver to be larger compared to untreated tumour-bearing mice, but when treated with a combination of rHIL-2 and rIFN-alpha A/D these organs were smaller than when rHIL-2 was administered alone. Thymocytes were drastically changed when mice were bearing a tumour or were treated with a cytokine. Especially immature T-cells, Lyt-2+/L3T4+, were drastically decreased in tumour-bearing mice, but were maintained following administration of rHIL-2 or rIFN-alpha A/D. When treated with rHIL-2 plus rIFN-alpha A/D, Lyt-2+/L3T4+ T-cells were decreased while Lyt-2+/L3T4- T-cells were increased. Frequency of immature T-cells, Lyt-2-/L3T4-, was not changed. On the other hand, T-cell subsets of splenocytes were markedly decreased in tumour-bearing mice compared to normal mice, but all the subsets of splenocytes were almost unchanged even when tumour-bearing mice were treated with rHIL-2 plus rIFN-alpha A/D. Thus, injection of rHIL-2 and rIFN-alpha A/D to tumour-bearing mice resulted in induction of Lyt-2+/L3T4- and asialo GM1+ cells in the peritoneal cavity, and the frequencies correlated with the observed antitumour activity in vivo in this murine model. The increase in Lyt-2+/L3T4- T-cells in the peritoneal cavity may be related to changes in the T-cells in thymus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786729      PMCID: PMC2246732          DOI: 10.1038/bjc.1989.187

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Interferon: a cytotoxic T lymphocyte differentiation signal.

Authors:  L K Chen; B Tourvieille; G F Burns; F H Bach; D Mathieu-Mahul; M Sasportes; A Bensussan
Journal:  Eur J Immunol       Date:  1986-07       Impact factor: 5.532

2.  In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.

Authors:  M Iigo; M Sakurai; T Tamura; N Saijo; A Hoshi
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

3.  CD4-/CD8-T cells: amplification in spleens of mice following in vivo treatment with monoclonal antibody anti-L3T4.

Authors:  T H Ermak; H J Steger
Journal:  Eur J Immunol       Date:  1988-02       Impact factor: 5.532

4.  Functional and biochemical characteristics of a murine interleukin 2 receptor-inducing factor.

Authors:  C Hardt; N Sato; H Wagner
Journal:  Eur J Immunol       Date:  1987-02       Impact factor: 5.532

5.  Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; S L Schwarz; P J Spiess
Journal:  J Natl Cancer Inst       Date:  1988-11-02       Impact factor: 13.506

6.  Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

Authors:  R B Cameron; J K McIntosh; S A Rosenberg
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

7.  In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells.

Authors:  M J Brunda; D Bellantoni; V Sulich
Journal:  Int J Cancer       Date:  1987-09-15       Impact factor: 7.396

8.  Up-regulation of interleukin 4 receptor expression on immature (Lyt-2-/L3T4-) thymocytes.

Authors:  J W Lowenthal; J Ransom; M Howard; A Zlotnik
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

9.  Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen.

Authors:  L L Lanier; D W Buck; L Rhodes; A Ding; E Evans; C Barney; J H Phillips
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

10.  Proliferation of thymic stem cells with and without receptors for interleukin 2. Implications for intrathymic antigen recognition.

Authors:  J P Lugo; S N Krishnan; R D Sailor; P Koen; T Malek; E Rothenberg
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  5 in total

Review 1.  [Role of the spleen in tumor surgery].

Authors:  U Wolters; H W Keller; H Pichlmaier
Journal:  Langenbecks Arch Chir       Date:  1991

2.  Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.

Authors:  Z Gazit; D W Weiss; D Shouval; M Yechezkeli; V Schirrmacher; M Notter; J Walter; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

4.  Enhanced therapeutic effects of anti-tumour agents against growth and metastasis of colon carcinoma 26 when given in combination with interferon and interleukin-2.

Authors:  M Iigo; H Tsuda; M Moriyama
Journal:  Clin Exp Metastasis       Date:  1994-11       Impact factor: 5.150

5.  Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.

Authors:  A von Rohr; A K Ghosh; N Thatcher; P L Stern
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.